

## Losatuxizumab

Cat. No.:	HY-P99715
CAS No.:	1801544-27-3
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC <sub>50</sub> s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR <sup>C271A,C283A</sup> , 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers <sup>[1][2]</sup> .								
In Vitro	Losatuxizumab (0.001 nM-100 nM) binds to EGFRvIII-expressing cell line U87MGde2-7 <sup>[1]</sup> . Losatuxizumab inhibits EGF-mediated EGFR phosphorylation in a NR6 huEGFR <sup>C271A,C283A</sup> cell line, with an IC <sub>50</sub> of 1.2 nM <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	<p>Lorigerlimab has antitumor activities in various wild-type EGFR-expressing squamous cell carcinoma xenograft model<sup>[1]</sup>. Lorigerlimab (40 mg/kg, i.p.) significantly inhibits growth of U87MGde2-7 tumor in mice<sup>[1]</sup>. Lorigerlimab (10 and 40 mg/kg, i.p.) prolongs survival and reduces levels of pEGFR in PDX GBM model (SN0207 tumor)<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>PDX GBM model (SN0207 tumor)<sup>[1]</sup></td></tr><tr><td>Dosage:</td><td>40 mg/kg</td></tr><tr><td>Administration:</td><td>i.p.</td></tr><tr><td>Result:</td><td>Prolonged survival rate, and reduced levels of pEGFR in tumor.</td></tr></table>	Animal Model:	PDX GBM model (SN0207 tumor) <sup>[1]</sup>	Dosage:	40 mg/kg	Administration:	i.p.	Result:	Prolonged survival rate, and reduced levels of pEGFR in tumor.
Animal Model:	PDX GBM model (SN0207 tumor) <sup>[1]</sup>								
Dosage:	40 mg/kg								
Administration:	i.p.								
Result:	Prolonged survival rate, and reduced levels of pEGFR in tumor.								

### REFERENCES

- [1]. Reilly EB, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51.
- [2]. Phillips AC, et al. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther. 2016 Apr;15(4):661-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA